Dark

XNCR
Xencor, Inc.
stock NASDAQ

Market Open

Aug 24, 2026 3:17:55 PM EDT

29.08USD+4.586%(+1.28)484,154

24.84Bid 29.09Ask 4.25Spread

Pre-market

Aug 24, 2026 8:04:30 AM EDT

27.66USD-0.504%(-0.14)705

After-hours

Aug 21, 2026 4:37:30 PM EDT

27.80USD0.000%(0.00)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 11, 2022

08:01AM EST Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones Business Wire

Jan 6, 2022

04:01PM EST Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference Business Wire

Dec 15, 2021

10:05AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021 Benzinga

06:40AM EST HC Wainwright & Co. Initiates Coverage On Xencor with Buy Rating, Announces Price Target of $61 Benzinga

Dec 12, 2021

09:23AM EST Xencor Presented Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at ASH 2021; Said Objective Response Rate was 51% (24/47); Complete Responses Were Observed in 12 Patients (26%) Benzinga

09:03AM EST Xencor Presents Data From Phase 1 Study Of Plamotamab In B-cell Non-Hodgkin Lymphomas At ASH Annual Meeting RTTNews

07:00AM EST Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting Business Wire

Nov 24, 2021

02:06PM EST Pfizer Sues Former Employee For Stealing Confidential Info On Its Megablockbuster COVID-19 Vaccine Benzinga

Nov 22, 2021

07:07AM EST Xencor Outlicenses Autoimmune Disease Candidate To Zenas BioPharma Benzinga

05:00AM EST Zenas BioPharma Announced Sunday it had Acquired Exclusive Worldwide Rights to Obexelimab from Xencor for Rights to Acquire Additional Zenas Equity Plus Up to $480M in Milestone Payments Benzinga

Nov 21, 2021

08:11PM EST Zenas BioPharma has acquired from Xencor Inc. (XNCR) exclusive worldwide rights to develop, manufacture and commercialize the investigational antibody obexelimab. RTTNews

07:59PM EST Zenas BioPharma Acquires Worldwide Rights To Obexelimab From Xencor RTTNews

06:00PM EST Xencor receives rights to additional equity in Zenas as upfront payment and is eligible for up to $480 million in potential milestone payments and royalties on net sales of commercialized products GlobeNewswire Inc

06:00PM EST Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor Business Wire

Nov 19, 2021

04:01PM EST Xencor to Present at Upcoming Investor Conferences Business Wire

Nov 12, 2021

07:29AM EST Xencor, in an updated on phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, said data from early-stage studies suggested that PD-1 and CTLA-4 inhibition has promise in prostate cancer, an area with high unmet need and without much checkpoint use. RTTNews

07:06AM EST Xencor Presents Updated Data From Phase 1 Study Of Vudalimab, PD-1 X CTLA-4 Bispecific Antibody RTTNews

07:00AM EST Xencor Presents Data from Multiple Preclinical XmAb(r) Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting Business Wire

07:00AM EST Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting Business Wire

Nov 9, 2021

11:16AM EST Xencor: Q3 Earnings Insights Benzinga

11:04AM EST Xencor Q3 EPS $(0.69) Misses $(0.65) Estimate, Sales $19.68M Beat $19.04M Estimate Benzinga

Nov 8, 2021

04:01PM EST Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306 Business Wire

05:06AM EST Earnings Scheduled For November 8, 2021 Benzinga

Nov 5, 2021

11:32AM EDT Preview: Xencor's Earnings Benzinga

Nov 4, 2021

09:22AM EDT Xencor To Present Data From The Phase 1 Study Of Plamotamab In B-cell Malignancies At The American Society Of Hematology Annual Meeting Benzinga

Nov 3, 2021

09:22AM EDT Xencor To Present Clinical Data From Phase 1 Study Of Tidutamab In Neuroendocrine Tumors At NANETS' Multidisciplinary NET Medical Virtual Symposium Nov. 6 Benzinga

09:06AM EDT Xencor Presents Clinical Data From Phase 1 Study Of Tidutamab In Neuroendocrine Tumors At NANETS RTTNews

09:00AM EDT Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS' Multidisciplinary NET Medical Virtual Symposium Business Wire

Nov 2, 2021

04:01PM EDT Xencor to Present at Upcoming Investor Conferences Business Wire

Nov 1, 2021

04:01PM EDT Xencor to Host Third Quarter 2021 Financial Results Webcast and Conference Call on November 8, 2021 Business Wire

Oct 4, 2021

07:12AM EDT Xencor Enters Global Collaboration And License Agreement With Benzinga

07:12AM EDT Xencor Enters Global Collaboration And License Agreement With Janssen To Advance Plamotamab And XmAb CD28 Bispecific Antibody Combinations For The Treatment Of Patients With B-Cell Malignancies; Xencor To Receive $100M Upfront Payment And $25M Equity Benzinga

07:00AM EDT Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies Business Wire

Oct 1, 2021

08:08AM EDT Xencor To Present Data From Phase 1 Study Of Vudalimab And Four Research Programs At SITC Annual Meeting RTTNews

08:01AM EDT Xencor to Present Data from the Phase 1 Study of Vudalimab (XmAb(r)717) and Four Research Programs at the SITC Annual Meeting Business Wire

Sep 20, 2021

04:01PM EDT Xencor to Present at the 2021 Cantor Virtual Global Healthcare Conference Business Wire

Aug 27, 2021

07:35AM EDT The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration Benzinga

Aug 20, 2021

02:04PM EDT Return on Capital Employed Insights for Xencor Benzinga

Aug 17, 2021

06:37AM EDT Incyte Out Licenses Lymphoma Drug To InnoCare In Greater China Benzinga

Aug 5, 2021

06:10AM EDT SVB Leerink Maintains Outperform on Xencor, Lowers Price Target to $53 Benzinga

Aug 4, 2021

04:28PM EDT Xencor Q2 EPS $0.87 Up From $(0.61) YoY, Sales $67.45M Up From $13.09M YoY Benzinga

04:01PM EDT Xencor Reports Second Quarter 2021 Financial Results Business Wire

07:52AM EDT The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings Benzinga

04:10AM EDT Earnings Scheduled For August 4, 2021 Benzinga

Aug 2, 2021

04:01PM EDT Xencor to Present at Upcoming Investor Conferences Business Wire

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 28, 2021

04:01PM EDT Xencor to Host Second Quarter 2021 Financial Results Webcast and Conference Call on August 4, 2021 Business Wire

May 27, 2021

04:01PM EDT Xencor to Present at the Jefferies Virtual Healthcare Conference Business Wire

09:53AM EDT Xencor Late Wednesday Reports Sotrovimab, an Investigational Antibody Utilizing Xencor's Xtend Technology, Receives U.S. FDA Emergency Use Authorization for the Treatment of COVID-19 Benzinga

May 26, 2021

09:37PM EDT The U.S. Food and Drug Administration has granted an emergency use authorization for a COVID-19 antibody drug made by GlaxoSmithKline (GSK, GSK.L) and Vir Biotechnology. RTTNews

08:43PM EDT Xencor: Sotrovimab Receives FDA EUA For Treatment Of Mild-to-moderate COVID-19 In Adults And Pediatric Patients RTTNews

07:46PM EDT Sotrovimab (VIR-7831), an Investigational Antibody Utilizing Xencor's Xtend(tm) Technology, Receives U.S. FDA Emergency Use Authorization for the Treatment of COVID-19 Business Wire

May 25, 2021

11:15AM EDT Bristol Myers Licenses Xencor's Technology Platform to Extend Half-Life of COVID-19 Antibodies Benzinga

08:33AM EDT Xencor, Bristol Myers Ink License Deal To Use Xtend XmAb RTTNews

08:06AM EDT Xencor Enters Technology License Agreement With Bristol-Myers Squibb RTTNews

08:03AM EDT Xencor Reports Technology License Deal With Bristol-Myers Squibb For BMY's Non-Exclusive Access To Xencor's Xtend Fc Technology, No Terms Disclosed Benzinga

08:01AM EDT Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend(tm) XmAb(r) Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19 Business Wire

May 12, 2021

04:01PM EDT Xencor to Present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference Business Wire

May 5, 2021

04:12PM EDT Xencor Q1 EPS $(0.04) Up From $(0.14) YoY, Sales $33.97M Up From $32.38M YoY Benzinga

04:01PM EDT Xencor Reports First Quarter 2021 Financial Results Business Wire

04:16AM EDT Earnings Scheduled For May 5, 2021 Benzinga

May 4, 2021

10:30AM EDT Xencor's Earnings: A Preview Benzinga

Apr 28, 2021

04:10PM EDT Xencor Doses First Subject in Phase 1 Study of XmAb564, an Engineered IL-2 Cytokine in Development for Autoimmune Diseases Benzinga

04:00PM EDT Xencor to Host First Quarter 2021 Financial Results Webcast and Conference Call on May 5, 2021 Business Wire

Apr 20, 2021

08:07AM EDT The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex Benzinga

Apr 15, 2021

07:49AM EDT The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split Benzinga

Apr 12, 2021

10:05AM EDT Xencor Saturday Morning Announced New Data From Multiple XmAb Bispecific Antibody and Cytokine Programs At American Association For Cancer Research Conference Benzinga

Apr 10, 2021

08:30AM EDT Xencor Presents Data from Multiple Preclinical XmAb(r) Bispecific Antibody and Cytokine Programs at the AACR Annual Meeting 2021 Business Wire

Mar 23, 2021

04:00AM EDT Lead product candidate, ZB001, has first-in-class potential in China for Thyroid Eye Disease GlobeNewswire Inc

Mar 10, 2021

08:15PM EST Xencor to Present Preclinical Data from Four Preclinical XmAb(r) Bispecific Antibody and Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2021 Business Wire

Mar 3, 2021

04:01PM EST Xencor to Present at the Barclays Global Healthcare Conference Business Wire

Feb 25, 2021

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

07:15AM EST Xencor, UCLA Ink Collaboration Pact For XmAb Therapeutic Candidates Benzinga

05:08AM EST Xencor And UCLA Collaborate To Develop Novel XmAb(r) Therapeutics RTTNews

05:01AM EST Xencor and UCLA Enter Collaboration to Discover and Develop Novel XmAb(r) Therapeutics Business Wire

Feb 24, 2021

10:07AM EST Benzinga's Top Ratings Upgrades, Downgrades For February 24, 2021 Benzinga

07:18AM EST Raymond James Upgrades Xencor to Outperform, Announces $58 Price Target Benzinga

Feb 23, 2021

04:22PM EST Recap: Xencor Q4 Earnings Benzinga

04:21PM EST Xencor Sees Ending 2021 With $425M-$475M In Cash, Cash Equivalents And Marketable Securities Benzinga

04:10PM EST Xencor Q4 EPS $(0.24) Beats $(0.38) Estimate, Sales $41.85M Beat $29.46M Estimate Benzinga

04:01PM EST Xencor Reports Fourth Quarter and Full Year 2020 Financial Results Business Wire

07:25AM EST The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts Benzinga

04:09AM EST Earnings Scheduled For February 23, 2021 Benzinga

Feb 16, 2021

04:02PM EST Xencor to Host Fourth Quarter and Full Year 2020 Financial Results Webcast and Conference Call on February 23, 2021 Business Wire

Feb 10, 2021

07:34AM EST The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs Benzinga

Feb 9, 2021

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

Feb 4, 2021

04:01PM EST Xencor to Present at Upcoming Investor Conferences Business Wire

Jan 22, 2021

07:22AM EST The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa Benzinga

Jan 21, 2021

08:05AM EST The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping Benzinga

Jan 12, 2021

08:16AM EST The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue Benzinga

Jan 11, 2021

12:13PM EST Xencor Reports In 13G Filing A 7.6% Stake In Miragen Therapeutics Benzinga

Jan 8, 2021

07:25AM EST The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs Benzinga

Jan 6, 2021

04:03PM EST Xencor, MD Anderson Enter Strategic Collaboration To Develop Novel T Cell-Engaged Bispecific Antibodies For Potential Treatment Of Patients With Cancer Benzinga

04:01PM EST Xencor and MD Anderson Enter Strategic Collaboration to Develop Novel T Cell-Engaging Bispecific Antibodies for Potential Treatment of Patients with Cancer Business Wire

Dec 17, 2020

08:10AM EST The Daily Biotech Pulse: MacroGenics Breast Cancer Drug Wins FDA Approval, Adcom Test Awaits Moderna, Virios To Make Wall Street Debut Benzinga

Dec 16, 2020

07:15AM EST The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal Benzinga

Dec 15, 2020

07:52AM EST The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding Benzinga

Dec 7, 2020

08:08AM EST Xencor Enters Research Collaboration And License Agreement With Janssen Biotech RTTNews

08:07AM EST Xencor Enters Collaboration With Janseen With Aim To Discover Novel CD28 Bispecific Antibodies For Treatment Of Prostate Cancer Benzinga

08:01AM EST Xencor Enters Collaboration with Janssen with Aim to Discover Novel CD28 Bispecific Antibodies for the Treatment of Prostate Cancer Business Wire

Dec 6, 2020

05:00PM EST Xencor Presents Updated Data from the Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia at the 2020 ASH Annual Meeting Business Wire

08:41AM EST Week Ahead In Biotech: FDA To Decide On Emergency Use Of Pfizer's COVID Vaccine, Hematology Conference Presentations Pick Up Pace Benzinga

Nov 12, 2020

04:01PM EST Xencor to Present at Upcoming Investor Conferences Business Wire

07:44AM EST The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal Benzinga

Nov 11, 2020

05:12PM EST Xencor (XNCR), MorphoSys AG (MORMOR) and Incyte (INCY) Wednesday announced a clinical collaboration to investigate the combination of tafasitamab, plamotamab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma and relapsed or refractory follicular lymphoma. RTTNews

04:24PM EST Xencor, MorphoSys And Incyte Enter Into Global Development Collaboration For Tafasitamab In Combination With Plamotamab, No Terms Disclosed Benzinga

04:04PM EST Xencor, MorphoSys And Incyte Announce Clinical Collaboration For Tafasitamab In Combination With Plamotamab RTTNews

04:04PM EST Xencor, MorphosSys, Incyte Enter Into Global Development Collaboration For Tafisitamab In Combination With Plamotamab Benzinga

04:02PM EST Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab Business Wire

Nov 9, 2020

08:14AM EST Xencor Reports Presentation Of Data From Multiple Preclinical XmAb Bispecific Antibody, Cytokine Programs At Society For Immunotherapy Of Cancer Benzinga

08:00AM EST Xencor Presents Data from Multiple Preclinical XmAb(r) Bispecific Antibody and Cytokine Programs at the SITC Annual Meeting Business Wire

08:00AM EST Xencor Presents Updated Data From the DUET-2 Phase 1 Study of XmAb20717, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting Business Wire

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 6, 2020

04:51AM EST SVB Leerink Maintains Outperform on Xencor, Raises Price Target to $46 Benzinga

Nov 5, 2020

04:07PM EST Xencor Q3 EPS $(0.22) Beats $(0.23) Estimate, Sales $35.37M Beat $33.44M Estimate Benzinga

04:01PM EST Xencor Reports Third Quarter 2020 Financial Results Business Wire

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 4, 2020

10:15AM EST Xencor To Present Data From Phase 1 Study Of Vibecotamab In Acute Myeloid Leukemia At The 2020 ASH Annual Meeting Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 29, 2020

04:01PM EDT Xencor to Host Third Quarter 2020 Financial Results Webcast and Conference Call on November 5, 2020 Business Wire

Oct 14, 2020

05:00PM EDT Xencor to Present Data from the Phase 1 Study of XmAb(r)20717 and Three Research Programs at the SITC Annual Meeting Business Wire

Oct 2, 2020

09:04AM EDT Xencor Presents Initial Data From Phase 1 Study Of Tidutamab At NANETS' Multidisciplinary NET Medical Virtual Symposium RTTNews

09:01AM EDT Xencor Highlights Presentation Of Initial Data From Phase 1 Study Of Tidutamab In Neuroendocrine Tumors At NANETS Multidisciplinary NET Medical Virtual Symposium Benzinga

09:00AM EDT Xencor Presents Initial Data From the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS' Multidisciplinary NET Medical Virtual Symposium Business Wire

Sep 9, 2020

04:01PM EDT Xencor to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference Business Wire

08:01AM EDT Xencor to Present Initial Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS' Multidisciplinary NET Medical Virtual Symposium Business Wire

Sep 8, 2020

07:01AM EDT SVB Leerink Maintains Outperform on Xencor, Lowers Price Target to $39 Benzinga

Sep 3, 2020

08:03AM EDT Xencor and MD Anderson Enter Strategic Collaboration to Advance Investigational XmAb Drug Candidates Benzinga

Aug 5, 2020

04:01PM EDT Xencor to Present at Upcoming Investor Conferences Business Wire

05:04AM EDT SVB Leerink Maintains Outperform on Xencor, Lowers Price Target to $42 Benzinga

Aug 4, 2020

04:04PM EDT Xencor Q2 EPS $(0.61) Misses $(0.50) Estimate, Sales $13.09M Beat $12.61M Estimate Benzinga

04:01PM EDT Xencor Reports Second Quarter 2020 Financial Results Business Wire

05:19AM EDT Earnings Scheduled For August 4, 2020 Benzinga

Jul 31, 2020

10:49PM EDT Xencor Earns Milestone Payment from MorphoSys for FDA Approval of Monjuvi(r) (tafasitamab-cxix) in the United States Business Wire

Jul 28, 2020

05:01PM EDT Xencor to Host Second Quarter 2020 Financial Results Webcast and Conference Call on August 4, 2020 Business Wire

.dark-mode .xRG6L6{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .xRG6L6{ color: #333333; background-color: white; border: 2px solid #333333; }XNCRXencor, Inc.stock NASDAQ

XNCR
Xencor, Inc.
stock NASDAQ